Linlin Luo, Ph.D. Large Pharma Merck & Co.

QUALIFICATIONS • Bioanalytical Sciences professional with 14 years of pharmaceutical industry experience. Extensive experience in pharmacokinetic (PK), immunogenicity (IMG or ADA), and neutralizing antibody (NAb) assay development and validation (e.g., measurement of drug, ligand, anti-drug antibody and neutralizing antibody), in support of preclinical and clinical studies using multiple platforms (e.g., MSD, ELISA, Gyros, Alphalisa, LC-MS hybrid). Contributed to multiple successful IND and BLA submissions.

EXPERIENCE • 2019-present Merck & Co. Inc Kenilworth, NJ 2019 Principal Scientist, Regulated Immunogenicity and Molecular Team, PPDM • 2010-2019 Bristol-Myers Squibb Princeton, NJ 2017 Senior Research Investigator II, BioAnalytical Sciences (BAS), Translational Medicine 2013 Senior Research Investigator I, BAS, Analytical & Bioanalytical Development 2010 Research Investigator II, BAS, Analytical & Bioanalytical Development • 2006-2010 Medarex, Inc Bloomsbury, NJ 2008 Scientist II, Preclinical Development 2006 Scientist I, Preclinical Development • 2005–2006 Johnson & Johnson PRD, LLC. Raritan, NJ Postdoctoral Fellow, Drug/Device Pharmacology • 2003–2005 Columbia University Medical Center New York, NY Postdoctoral Research Fellow, Dept. of Pathology

EDUCATION Ph.D. Biochemistry, The City University of New York, New York, NY M.Ph. Biochemistry, The City University of New York, New York, NY B.S. Microbiology, Shandong University, China

AWARDS/MEMBERSHIP

2018 Bravo Ovation 2 (the 2nd most prestigious BMS award) Award on Opdivo China Approval, Bristol-Myers Squibb 2018 Celebrate Bravo Award for China Filing for Opdivo Approval, Bristol- Myers Squibb 2018 Well Done Bravo Award for Successful NAb Transfer for Elotuzumab and 1st DBL, Bristol-Myers Squibb 2017 Encore Bravo Award for Relatlimab DP5 Achievement, Bristol-Myers Squibb 2016-present CPSA Organizing Committee 2010-present The American Association of Pharmaceutical Scientists (AAPS)